Single-interface bioelectronic medicines - concept, clinical applications and preclinical data

Author: Cristian Sevcencu1
1 National Institute for Research and Development of Isotopic and Molecular Technologies, 67-103 Donat Street, Cluj-Napoca, 400293, ROMANIA.
Conference/Journal: J Neural Eng
Date published: 2022 May 9
Other: Special Notes: doi: 10.1088/1741-2552/ac6e08. , Word Count: 184

Presently, large groups of patients with various diseases are either intolerant, or irresponsive to drug therapies and also intractable by surgery. For several diseases, one option which is available for such patients is the implantable neurostimulation therapy. However, lacking closed-loop control and selective stimulation capabilities, the present neurostimulation therapies are not optimal and are therefore used as only "third" therapeutic options when a disease cannot be treated by drugs or surgery. Addressing those limitations, a next generation class of closed-loop controlled and selective neurostimulators generically named bioelectronic medicines seems within reach. A sub-class of such devices is meant to monitor and treat impaired functions by intercepting, analyzing and modulating neural signals involved in the regulation of such functions using just one neural interface for those purposes. The primary objective of this review is to provide a first broad perspective on this type of single-interface devices for bioelectronic therapies. For this purpose, the concept, clinical applications and preclinical studies for further developments with such devices are here analyzed in a narrative manner.

Keywords: bioelectronic medicines; closed-loop control; neuromodulation; vagus nerve.

PMID: 35533654 DOI: 10.1088/1741-2552/ac6e08